Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate (or whose legal representative has done so on their behalf)
• People aged 18 or older
• People whose overall health and ability to carry out daily activities meets a certain level of functioning, as measured by a standard medical scale (ECOG score of 2 or below)
• People who have been diagnosed with multiple myeloma
• People who have already been treated with at least 4 previous lines of therapy, including one from each of these three types: an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody
• People who received the commercially available CAR T-cell therapy idecabtagene vicleucel (Abecma) as prescribed according to FDA-approved guidelines (people who received a non-conforming product but were originally prescribed it correctly may also be considered, at the investigator's discretion)
• People who are between 30 and 90 days after receiving idecabtagene vicleucel (Abecma)
• People whose disease was at least stable in response to idecabtagene vicleucel
• People who have fully recovered from the side effects of prior cancer treatments, including idecabtagene vicleucel, with only mild or no remaining side effects (except hair loss)
• People whose blood cell counts, liver function, and kidney function fall within acceptable ranges as confirmed by blood tests taken within 14 days before starting the study treatment
• People whose blood oxygen level is above 92% while breathing normal air
• Women of childbearing potential who have a negative pregnancy test within 14 days before starting the study treatment
• Women of childbearing potential and men who agree to follow the pregnancy prevention guidelines required for the study drug mezigdomide (CC-92480)

Who may not be able to join:

• People who have previously been treated with mezigdomide (CC-92480)
• People who are currently using or planning to use other cancer treatments alongside mezigdomide
• People who are currently receiving, or are likely to need, medications that suppress the immune system (very low-dose steroids equivalent to 5 mg/day or less of prednisone are permitted)
• People taking certain medications that interact with how the body processes drugs (known as CYP3A4/5 inhibitors or inducers)
• People taking proton pump inhibitors (a common type of medication used to reduce stomach acid)
• People whose myeloma has relapsed, as determined by their treating doctor or study investigator
• People whose myeloma has spread to the central nervous system (brain or spinal cord)
• People who still have ongoing side effects from cytokine release syndrome (CRS) or brain/nerve-related side effects (ICANS) from their CAR T-cell therapy
• People with a history of serious allergic reactions to drugs that are chemically or biologically similar to the study drug
• People who have tested positive for COVID-19 (by PCR test), or who have an active uncontrolled infection requiring antibiotics within 7 days of starting the study drug
• People who are HIV-positive with a CD4+ T cell count below 200 (a measure of immune system strength)
• People who are pregnant or breastfeeding
• People with any other medical condition that, in the investigator's judgment, would make participation unsafe
• People who, in the investigator's opinion, may not be able to follow all the required study procedures

Important: Always verify eligibility with the trial site directly before applying.